NCT06238661Enrolling by invitation
Prostate Cancer Screening: a Pilot Study
Prostate Cancer Screening With PSA, Risk Calculator and Multiparametric MRI: a Pilot Study
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 4500 (estimated)
- First submitted
- 25 Jan 2024
- Start date
- 17 Feb 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Fondazione del Piemonte per l'Oncologia
- Diseases
- Prostate cancer
- NCT number
- NCT06238661
What you commit to
- Study type: Interventional
- Planned participants: 4500
- From 17 Feb 2025 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous biopsy or prostate surgery;
- previous radiotherapy of the pelvis;
Other illness
- positive oncologic anamnesis for prostate cancer;
Other
- any contraindication to MRI examination;
- claustrophobic or uncollaborative subjects.
Who the study is looking for
- age between 55-65 years;
- asymptomatic or paucisymptomatic from a urological point of view;
- no previous prostate biopsy;
- living in the ASL TO5 (Piedmont, Italy);
- signed written informed consent.
Age in the registry: 55 years to 65 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione del Piemonte per l'Oncologia Coordinator of this site? Confirm its status | Candiolo | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.